pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
COMPANY OVERVIEW
Avillion's objective is to enable their partners to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves
LOCATION
London, , UK
THERAPEUTIC AREAS
WEBSITE
https://avillionllp.com/
CAREER WEBSITE
None
SOCIAL MEDIA
INVESTORS
PRESS RELEASES
May 31, 2022
US FDA accepts New Drug Application filed by Avillion for AstraZeneca's PT027 for the as-needed treatment or prevention of symptoms in asthma patients
May 15, 2022
Avillion announces publication of positive full results from MANDALA Phase III trial of AstraZeneca's PT027 in asthma patients in the New England Journal of Medicine
Sep 9, 2021
Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients
Apr 23, 2021
Avillion's positive Phase 2 trial of tri-specific Nanobody sonelokimab (M1095) in chronic psoriasis published in The Lancet
Oct 29, 2020
Positive results from Avillion's Phase 2 trial of sonelokinab (M1095) in chronic psoriasis to be presented today in Late-Breaking News Session at EADV 2020 Virtual
For More Press Releases